WILMINGTON, Del., Jan. 25, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of SuperCom Ltd. (NASDAQ:SPCB)?
- Did you purchase your shares between June 1, 2015 and November 27, 2015, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. reminds shareholders of SuperCom Ltd. (“SuperCom” or the “Company”) (NASDAQ:SPCB) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. A complaint was filed in the United States District Court for the Southern District of New York on behalf of all persons or entities that purchased the common stock of SuperCom between June 1, 2015 and November 27, 2015, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you wish to serve as lead plaintiff, you must move the Court no later than February 8, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you purchased shares of SuperCom during the Class Period, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/supercom-ltd-spcb.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com


Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Washington Post Publisher Will Lewis Steps Down After Layoffs
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 



